NEURO61

Session information

Print

Symposium

[S-29] Symposium 29
Preparing for disease-modifying therapies in PD – From biomarkers, animal models to novel therapeutic approach

Tue. Sep 1, 2020 10:45 AM - 12:15 PM Room 6 (OKAYAMA CONVENTION CENTER 2F Reception Hall)

Chair：CarolynSue（The University of Sydney）,ShigekiArawaka（Department of Internal Medicine IV, Division of Neurology, Osaka Medical College）

[S-29-1] Updates of Liquid biomarkers in PD

○Chin-Hsien Lin, Chau-chung Wu, Ming-jang Chiu (National Taiwan University Hospital)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

[S-29-2] Updates of liquid biomarkers and disease-modifying potential of an antiparkinsonian drug in PD

○Shigeki Arawaka (Department of Internal Medicine IV, Division of Neurology, Osaka Medical College, Japan)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

[S-29-3] Animal model for disease-modifying therapies in PD

○Hodaka Yamakado (Kyoto University Hospital, Japan)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

[S-29-4] Novel therapeutic strategies targeting mitochondria

○Carolyn M. Sue1,2 (1.Kolling Institute of Medical Research, Australia, 2.University of Sydney, Australia)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

[S-29-5] Disease-modifying therapeutics targeting alpha-synuclein

○Masayuki Nakamori (Department of Neurology, Osaka University Graduate School of Medicine, Japan)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.